<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216397</url>
  </required_header>
  <id_info>
    <org_study_id>1288.6</org_study_id>
    <secondary_id>2010-019291-75</secondary_id>
    <nct_id>NCT01216397</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers</brief_title>
  <official_title>Relative Bioavailability of Two Different Batches of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet (FDC) in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the relative bioavailability of two
      different batches of a 2.5 mg linagliptin / 1000 mg metformin fixed dose combination tablet
      (FDC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Linagliptin: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of Cmax of Linagliptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of AUC0-72 of Linagliptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin: Cmax</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric Mean of Cmax of Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin: AUC0-tz</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric Mean of AUC0-tz of Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: AUC0-infinity</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of AUC0-infinity of Linagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric Mean of percentage of AUCtz-∞ of linagliptin, where percentage is the unit of measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Median of the t_max of linagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: λz (Terminal Elimination Rate Constant in Plasma)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of the λ_z of linagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (Terminal Half-life of the Analyte in Plasma)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of the t1/2 of linagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of the MRTpo of linagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of the CL/F of linagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of the Vz/F of linagliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: AUC0-infinity</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric Mean of AUC0-infinity of Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric Mean of the percentage of AUCtz-infinity of Metformin, where percentage is the unit of measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: Tmax</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Median of tmax of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: λz (Terminal Elimination Rate Constant in Plasma)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of λz of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of t1/2 of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of MRTpo of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: CL/F</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of CL/F of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin: Vz/F</measure>
    <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
    <description>Geometric mean of Vz/F of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</measure>
    <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
    <description>12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
    <description>Number of patients with treatment emergent AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Discontinued the Trial Because of an Adverse Event</measure>
    <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
    <description>Number of participants who discontinued the trial because of an adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Tolerability by the Investigator</measure>
    <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
    <description>Qualitative variable assessing the tolerability by the investigator</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Linagliptin/Metformin (standard batch)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin/Metformin (side batch)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin/Metformin (standard batch)</intervention_name>
    <description>Fixed dose combination tablet</description>
    <arm_group_label>Linagliptin/Metformin (standard batch)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin/Metformin (side batch)</intervention_name>
    <description>Fixed dose combination tablet</description>
    <arm_group_label>Linagliptin/Metformin (side batch)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males and females according to the following criteria: Based upon a complete
             medical history, including physical examination, vital signs (blood pressure (BP),
             pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests

          2. Age 21 to 50 years (incl.)

          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts

          7. Chronic or relevant acute infections

          8. History of relevant allergy or hypersensitivity (including allergy to drug or its
             excipients)

          9. Intake of drugs within one month or less than 10 half-lives of the respective drug
             prior to first study drug administration

         10. Participation in another trial with an investigational drug within 2 months prior to
             administration or during the trial

         11. Smoker (more than 10 cigarettes or 3 cigars 3 pipes daily)

         12. Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in
             males)

         13. Drug abuse

         14. Blood donation (more than 100 mL within four weeks prior to day 1 of visit 2)

         15. Any laboratory value outside the reference range that is of clinical relevance

         16. Inability to comply with dietary regimen of trial site

             For female subjects of childbearing potential only:

         17. Positive pregnancy test, pregnancy or planning to become pregnant 1 month before study
             or within 2 months after study completion

         18. No adequate contraception 1 month before study and until 2 month after study
             completion, e.g. not any of the following: implants, injectables, combined hormonal
             contraceptives, hormonal IUD (intrauterine device), sexual abstinence for at least 1
             month prior to first study drug administration, vasectomised partner (vasectomy
             performed at least 1 year prior to enrolment), or surgical sterilisation (including
             hysterectomy). Females, who do not have a vasectomised partner, are not sexually
             abstinent or surgically sterile will be asked to use an additional barrier method
             (e.g. condom).

         19. Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1288.6.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <results_first_submitted>February 3, 2012</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2012</results_first_posted>
  <last_update_submitted>June 18, 2014</last_update_submitted>
  <last_update_submitted_qc>June 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was an open-label, single-dose, randomised, 2-way crossover trial. Subjects were equally randomised to one of two sequences, and in general terms, AB or BA. Hence, 20 subjects were in group AB and 20 in group BA. All 40 subjects received A and B. The numbers presented in the milestones are overall, which is consistent with the trial report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Batch Then Side Batch</title>
          <description>Linagliptin/metformin FDC tablet from standard batch, then Linagliptin/metformin FDC tablet from side batch</description>
        </group>
        <group group_id="P2">
          <title>Side Batch Then Standard Batch</title>
          <description>Linagliptin/metformin FDC tablet from side batch, then Linagliptin/metformin FDC tablet from standard batch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (35 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Treatment with standard batch and side batch</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.74" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin: Maximum Measured Concentration (Cmax)</title>
        <description>Geometric mean of Cmax of Linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Maximum Measured Concentration (Cmax)</title>
          <description>Geometric mean of Cmax of Linagliptin</description>
          <population>Treated Set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="20.3"/>
                    <measurement group_id="O2" value="5.39" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard batch vs. Side batch</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>99.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>94.2</ci_lower_limit>
            <ci_upper_limit>105.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)</title>
        <description>Geometric mean of AUC0-72 of Linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)</title>
          <description>Geometric mean of AUC0-72 of Linagliptin</description>
          <population>Treated Set</population>
          <units>nmol*hr/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" spread="21.6"/>
                    <measurement group_id="O2" value="179" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard batch vs. Side batch</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>100.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.1</ci_lower_limit>
            <ci_upper_limit>104.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: AUC0-infinity</title>
        <description>Geometric mean of AUC0-infinity of Linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: AUC0-infinity</title>
          <description>Geometric mean of AUC0-infinity of Linagliptin</description>
          <population>Treated Set</population>
          <units>nmol*hr/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" spread="25.4"/>
                    <measurement group_id="O2" value="267" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard batch vs. Side batch</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>100.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>94.7</ci_lower_limit>
            <ci_upper_limit>105.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation</title>
        <description>Geometric Mean of percentage of AUCtz-∞ of linagliptin, where percentage is the unit of measurement.</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Percentage of AUCtz-∞ Obtained by Extrapolation</title>
          <description>Geometric Mean of percentage of AUCtz-∞ of linagliptin, where percentage is the unit of measurement.</description>
          <population>Treated Set</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="17.5"/>
                    <measurement group_id="O2" value="32.1" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)</title>
        <description>Median of the t_max of linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Time to Maximum Measured Concentration of the Analyte in Plasma (Tmax)</title>
          <description>Median of the t_max of linagliptin</description>
          <population>Treated Set</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.667" upper_limit="6.02"/>
                    <measurement group_id="O2" value="3.00" lower_limit="0.983" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: λz (Terminal Elimination Rate Constant in Plasma)</title>
        <description>Geometric mean of the λ_z of linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: λz (Terminal Elimination Rate Constant in Plasma)</title>
          <description>Geometric mean of the λ_z of linagliptin</description>
          <population>Treated Set</population>
          <units>1/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0153" spread="17.1"/>
                    <measurement group_id="O2" value="0.0152" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 (Terminal Half-life of the Analyte in Plasma)</title>
        <description>Geometric mean of the t1/2 of linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 (Terminal Half-life of the Analyte in Plasma)</title>
          <description>Geometric mean of the t1/2 of linagliptin</description>
          <population>Treated Set</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="17.1"/>
                    <measurement group_id="O2" value="45.6" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)</title>
        <description>Geometric mean of the MRTpo of linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)</title>
          <description>Geometric mean of the MRTpo of linagliptin</description>
          <population>Treated Set</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="15.7"/>
                    <measurement group_id="O2" value="64.5" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)</title>
        <description>Geometric mean of the CL/F of linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Apparent Clearance of the Analyte in Plasma After Extravascular Administration (CL/F)</title>
          <description>Geometric mean of the CL/F of linagliptin</description>
          <population>Treated Set</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330" spread="25.4"/>
                    <measurement group_id="O2" value="330" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)</title>
        <description>Geometric mean of the Vz/F of linagliptin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Apparent Volume of Distribution During the Terminal Phase Following an Extravascular Dose (Vz/F)</title>
          <description>Geometric mean of the Vz/F of linagliptin</description>
          <population>Treated Set</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1300" spread="22.8"/>
                    <measurement group_id="O2" value="1300" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin: Cmax</title>
        <description>Geometric Mean of Cmax of Metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Cmax</title>
          <description>Geometric Mean of Cmax of Metformin</description>
          <population>Treated Set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1790" spread="23.0"/>
                    <measurement group_id="O2" value="1820" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard batch vs. Side batch</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>97.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.5</ci_lower_limit>
            <ci_upper_limit>103.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin: AUC0-tz</title>
        <description>Geometric Mean of AUC0-tz of Metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: AUC0-tz</title>
          <description>Geometric Mean of AUC0-tz of Metformin</description>
          <population>Treated Set</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12100" spread="21.4"/>
                    <measurement group_id="O2" value="12100" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>100.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.7</ci_lower_limit>
            <ci_upper_limit>105.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: AUC0-infinity</title>
        <description>Geometric Mean of AUC0-infinity of Metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: AUC0-infinity</title>
          <description>Geometric Mean of AUC0-infinity of Metformin</description>
          <population>Treated Set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12400" spread="21.2"/>
                    <measurement group_id="O2" value="12300" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Standard batch vs. Side batch</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>adjusted gMean ratio</param_type>
            <param_value>100.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.7</ci_lower_limit>
            <ci_upper_limit>105.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation</title>
        <description>Geometric Mean of the percentage of AUCtz-infinity of Metformin, where percentage is the unit of measurement.</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Percentage of AUCtz-∞ Obtained by Extrapolation</title>
          <description>Geometric Mean of the percentage of AUCtz-infinity of Metformin, where percentage is the unit of measurement.</description>
          <population>Treated Set</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="87.4"/>
                    <measurement group_id="O2" value="1.52" spread="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: Tmax</title>
        <description>Median of tmax of metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Tmax</title>
          <description>Median of tmax of metformin</description>
          <population>Treated Set</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="0.667" upper_limit="4.02"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.65" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: λz (Terminal Elimination Rate Constant in Plasma)</title>
        <description>Geometric mean of λz of metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: λz (Terminal Elimination Rate Constant in Plasma)</title>
          <description>Geometric mean of λz of metformin</description>
          <population>Treated Set</population>
          <units>1/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0493" spread="71.0"/>
                    <measurement group_id="O2" value="0.0514" spread="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma)</title>
        <description>Geometric mean of t1/2 of metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: t1/2 (Terminal Half-life of the Analyte in Plasma)</title>
          <description>Geometric mean of t1/2 of metformin</description>
          <population>Treated Set</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="71.0"/>
                    <measurement group_id="O2" value="13.5" spread="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)</title>
        <description>Geometric mean of MRTpo of metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: MRTpo (Mean Residence Time of the Analyte in the Body After Peroral Administration)</title>
          <description>Geometric mean of MRTpo of metformin</description>
          <population>Treated Set</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="31.1"/>
                    <measurement group_id="O2" value="8.23" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: CL/F</title>
        <description>Geometric mean of CL/F of metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: CL/F</title>
          <description>Geometric mean of CL/F of metformin</description>
          <population>Treated Set</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1350" spread="21.2"/>
                    <measurement group_id="O2" value="1350" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin: Vz/F</title>
        <description>Geometric mean of Vz/F of metformin</description>
        <time_frame>Day 1 to 35 for period 1, and Day 36 to 70 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin: Vz/F</title>
          <description>Geometric mean of Vz/F of metformin</description>
          <population>Treated Set</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1640" spread="74.3"/>
                    <measurement group_id="O2" value="1580" spread="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</title>
        <description>12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities</description>
        <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities</title>
          <description>12-lead-Electrocardiogram (ECG), vital sign (blood pressure and pulse rate), physical finding and laboratory abnormalities</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical examination abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vital sign abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory finding abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Treatment Emergent Adverse Events</title>
        <description>Number of patients with treatment emergent AEs</description>
        <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment Emergent Adverse Events</title>
          <description>Number of patients with treatment emergent AEs</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Discontinued the Trial Because of an Adverse Event</title>
        <description>Number of participants who discontinued the trial because of an adverse event</description>
        <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Discontinued the Trial Because of an Adverse Event</title>
          <description>Number of participants who discontinued the trial because of an adverse event</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Tolerability by the Investigator</title>
        <description>Qualitative variable assessing the tolerability by the investigator</description>
        <time_frame>Day 1 to 4 for period 1, and day 36 to 39 for period 2</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Batch</title>
            <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
          <group group_id="O2">
            <title>Side Batch</title>
            <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability by the Investigator</title>
          <description>Qualitative variable assessing the tolerability by the investigator</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 days (period 1) + 4 days (treatment period 2)</time_frame>
      <desc>Two identical treatment periods with an interval of at least 35 days between drug administrations.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Batch</title>
          <description>standard batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
        </group>
        <group group_id="E2">
          <title>Side Batch</title>
          <description>side batch of a 2.5 mg linagliptin/ 1000mg metformin FDC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

